SBC Medical Q3 10-Q: Revenue Up 35% to $59M, But Material Weaknesses Persist and Nasdaq Notice Stands
SBC has more than doubled off its 52-week low of $2.78.
Summary
SBC Medical's Q3 10-Q shows revenue up 35% to $58.6 million and net income up 22%, alongside confirmation that its material weaknesses are still un-remediated and a Nasdaq board-independence notice remains open.
Key Events · Earnings and Guidance · SBC
-
Q3 Revenue Jumps 35% to $58.6M
Total revenues, net rose to $58,581,520 for the three months ended September 30, 2026 from $43,353,235 a year earlier, a 35.13% increase, driven by management services revenue up 73.28% and rental services revenue up 29.64%.
-
Net Income Up 22% to $15.7M
Net income attributable to SBC Medical Group Holdings Incorporated was $15,692,742 versus $12,824,636, and income from operations rose 66.34% to $26,417,267.
-
Material Weaknesses Still Un-Remediated
Management concluded disclosure controls and procedures were not effective as of September 30, 2026 because the previously identified material weaknesses in internal control over financial reporting remained un-remediated.
-
Nasdaq Board Independence Notice Open
A July 10, 2026 Nasdaq notice confirmed non-compliance with Listing Rule 5605 board independence and audit committee size requirements; the cure period runs to the earlier of the next annual meeting or July 9, 2027.
Analysis · SBC · Industrial Applications And Services
The headline numbers are strong: Q3 revenue of $58.6 million rose 35% year over year and net income attributable to the company climbed 22% to $15.7 million, with nine-month operating cash flow flipping to positive $50.2 million from a $27.3 million outflow a year earlier. Against that, the 10-Q confirms the previously identified material weaknesses in internal control over financial reporting remained un-remediated as of September 30, 2026, and management concluded disclosure controls were not effective. It also discloses a July 10, 2026 Nasdaq notice that the company fell out of compliance with board independence and audit committee size rules after a director declined to stand for re-election, with a cure period running to the earlier of the next annual meeting or July 9, 2027. Growth is real, but the control and listing issues are the part that can reprice the stock.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBC was trading at $5.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $549.2M. The 52-week trading range was $2.78 to $5.79. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.